Skip to content

Galactooligosaccharide (GOS) Supplementation and Calcium Absorption in Girls

The Effect of Galactooligosaccharide (GOS) Supplementation on Calcium Absorption and Retention in Female Adolescent Girls

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01263847
Acronym
Friesland
Enrollment
31
Registered
2010-12-21
Start date
2009-06-30
Completion date
2010-07-31
Last updated
2018-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Keywords

Dietary Supplement: Galactooligosaccharide

Brief summary

The purpose of this study is to determine the effects of galactooligosaccharide (GOS) supplementation on calcium absorption and and gut microbe profiles.

Detailed description

Galactooligosaccharides (GOS) have been shown to have positive effects on calcium absorption in animals and postmenopausal women. This study aims to see whether the addition of fiber in the form of GOS to a calcium-containing yogurt drink will increase calcium absorption compared to placebo in a group of girls near menarche. Secondary outcomes are to assess physical fitness and determine the relationship between physical fitness and calcium absorption in adolescent girls as well as assess changes in gut microbiota. During this three phase, randomized, controlled crossover study, participants will consume yogurt drinks supplemented with 0, 2.5 or 5 grams of GOS twice daily for three weeks. Following each three week period, participants will complete a weekend clinical visit to measure calcium absorption. Height, weight, bone density and geometry, calcium absorption, gut microbiota and physical fitness will be measured. Effects of this GOS fiber intervention may help elucidate a mechanism of action for improving bone health with fiber supplementation.

Interventions

DIETARY_SUPPLEMENTGalactooligosaccharide

Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.

Sponsors

Friesland Foods
CollaboratorUNKNOWN
Purdue University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
10 Years to 12 Years
Healthy volunteers
Yes

Inclusion criteria

* Female between ages of 10 and 12 * Calcium intake of 900-1300 mg/d

Exclusion criteria

* Take medication that influences calcium metabolism * Any disorder of calcium or bone homeostasis * BMI\>90th percentile for age * Smoking, illegal drug consumption * Any gastrointestinal disease (crohn's disease, celiac disease, inflammatory bowel disease) * Any disease affecting kidney function * Broken bone within last 6 months * Dislike of yogurt or yogurt drinks * Regular use of foods containing probiotics or prebiotics

Design outcomes

Primary

MeasureTime frameDescription
Calcium Absorptionbaseline and 48 h urine and bloodCalcium absorption will be measured using dual isotope methods. Calcium-44(Ca-44) as calcium chloride will be administered in a yogurt drink provided at breakfast along with a roll, butter, jam and juice. A second isotope, Calcium-43 (Ca-43) as calcium chloride will be administered intravenously, one hour after consumption of breakfast. Urine and blood samples will be collected over a period of 48 hours and levels of Ca-44 and Ca-43 will be measured in urine and blood. Levels of Ca-44 and Ca-43 will be expressed as a ratio (Ca-44/Ca-43).

Secondary

MeasureTime frame
Change in fecal microbiotaafter 3 weeks of product consumption

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026